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Repeated Hepatic Dearterialization for
Unresectable Liver Metastases from Gastric
Cancer: Review of Five Cases
TAKEO KIMOTO, NAOFUMI NAGASUE, HITOSHI KOHNO, YU-CHUNG CHANG,
HIROYUKITANIURA, AKIRA YAMANOI,MASAAKI UCHIDA, YOSHINARI TAKEMOTO,
YOSHINARI MAKINO and TERUHISA NAKAMURA
From Second Department of Surgery, Shimane Medical University, Izumo 693, Japan
A novel method ofrepeated hepatic dearterialization was evaluated in five patients with multiple
metastases from gastric cancer in both hepatic lobes. After gastrectomy with extensive lymph node
dissection (R2/3), all patients underwent implantation ofa vascular occluder around the hepatic
artery. Cannulation ofthe hepatic artery was added for later chemotherapy. The hepatic artery was
occluded repeatedly for hour twice daily in combination with intrahepatic infusion ofanticancer
drugs for as long as possible. Three offive patients demonstrated marked tumour regression with
unexpectedly long survival (16 months in two patients and one still alive at 15 months).
Carcinoembryonic antigen (CEA) levels decreased to almost normal in four patientswho had initially
high levels. The present experiences seems to indicate that long survival can be hoped for in patients
with advanced gastric cancer with unresectable liver metastases.
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INTRODUCTION
The prognosis of gastric cancer has become much better
in Japan than in Western countries, mainly because ofthe
increasing proportion of "curative resections" because
of earlier detection of the disease 1. However, advanced
gastric cancers with peritoneal dissemination, hepatic
metastases or widespread nodal involvement are also not
infrequent in our country and the prognosis is still dismal
for such patients. In advanced gastric cancer, liver
metastases is one ofthe most ominous signs for prognosis
and the most common site of involvement3. Natural
history ofgastric cancer with the extensive liver metastases
is less than two months4. This report describes our
experience of five patients with gastric cancer who had
unresectable multiple liver metastases, treated by a novel
method of repeated hepatic dearterialization after
aggressive resection ofthe original lesions.
Addressforcorrespondence: Mr. T. Kimoto, SecondDepartment
of Surgery, Shimane Medical University, Izumo 693, Japan
MATERIALANDMETHODS
Patients
Between April, 1989 and February, 1992, five patients, four
men and one woman, were treated by repeated hepatic
arterial occlusion with intra-arterial infusion ofanticancer
drugs. The ages ranged between 52 and 73 years old. All
patients had multiple liver metastases from gastric cancer
without peritoneal dissemination. The liver tumours were
found synchronously in four patients and metachronously
in one (Table 1).
Operative technique
Gastrectomy with R2-R3 lymph node dissection was per-
formed in all patients. Four patients underwent partial
gastrectomy and the other total gastrectomy. Hepatic
bisegmentectomy (VI and VII) was performed in one
patient, with multiple liver recurrence after six months.
Implantation of vascular occluder was performed
simultaneously in four patients, and metachronously in
one patient. After dissection of all liver attachments, the
175176 T. KIMOTO et al.
Table 1 Summary of five cases
Case Sex Age TNM
Classification
Totaldoses ofinfusion
chemotherapy
Survival
time (Cause
ofdeath)
Reduction of
hepatic
tumours
M 59 T3N3M1
2 F 52 T3N2M1
3 M 72 T3NOM1
4 M 73 T2NOM1
5 M 66 T3N3M1
MMC 48mg, 5-FU 7000mg
MMC 46mg, 5-FU 19750mg
MMC 44 mg, 5-FU 1000mg
ADR45mg
MMC 4 mg
Epirubicin 200mg
MMC 56.8 mg
Epirubicin 284mg
16 months
(Extrahepatic
cancers)
16 months
(Extrahepatic
Cancers)
4 months
(Liver failure)
2 months
(Liver failure)
15 months
(alive)
77%
93%
35%
17o/0
89o/0
vascular occluder was placed round thecommon hepatic
.artery, and it was fixed to and wrapped with a sheath of
expanded polytetrafluoroethylene (PTFE). The PTFE
sheath was sutured encircling the artery and the balloon
occluder together. The end of the catheter from the
balloon was pulled out through the abdominal wall.
Injection of to 2 ml of saline could occlude the hepatic
artery by compression with the balloon. The necessary
volume for complete occlusion was confirmed at ope-
ration. The cannula for chemotherapy was inserted into
the gastroduodenal artery. The right gastric artery was
routinely ligated at its origin. (Fig. 1)
Postoperative treatment
The occlusionwas started from 5 to 8 days after operation.
Itwas performed for hour twice daily and repeated for as
long as possible. Three patients were instructed how to
occlude the hepatic artery and continued this therapy by
themselves at home. lntra-arterial infusion of 5-Fluor-
ouracil (5-FU), Mitomycin(MMC), Adfiamycin(ADR) or
Epirubicin were started from 8 to 11 days after operation
and intermittently repeated for long as possible. Three
patients were prescribed Carmofur (HCFU), 300 mg/day,
orally after discharge from hospital. The effectiveness of
the treatmentwas evaluated by carcinoembryonic antigen
(CEA) andcomputed tomography (CT).
Figure The vascular balloon occluder is placed beside the
common hepatic artery. They are wrapped together using
expanded PTFE vascular sheath. Injection of to 2 ml. ofsaline can
compress the hepatic artery. The right gastric artery is routinely
ligated.
CASEREPORTS
Case 1
This 59-year-oldman had multiple liver metastases from
gastric cancer. Both lobes ofthe liver were involved with
tumours. The primary gastric cancer was located in the
antrum and partially invaded the duodenum. Therewas no
peritoneal dissemination but involvement ofregional and
other intra-abdominal lymph nodes such as para-aortic,
hepatoduodenal and retropancreatic. He underwent
partial gastrectomy, and extensive dissection of these
lymph nodes. A vascular occluder was placed round the
common hepatic artery and the cannula inserted. Hepatic
arterial occlusion was started 8 days after operation for
one hour twice a day and repeated for nine months. The
occlusion time was reduced to once a day for a further
three months. Intra-arterial infusion ofMMC in a dose
of 24 mg and 5-FU, 500 mg was added on the 8th
postoperative day (POD). At 22 POD, the same doses
were administered. From 28POD for the next 12 days, 5-
FU in a dose of250 mg/daywas infused daily. HCFU, 300LIVER METASTASESFROM GASTRICCANCER 177
mg/day was given orally for 10 months after his discharge
from hospital. Fourmonths after the start oftreatment, all
tumours had became cystic lesions and showed 77 per
cent reduction on CT scan. Serial CEA level became
normal from 105 ng/ml at 3POD to 0.6 ng/ml fourmonths
later. The occlusion therapy was continued by the patient
at home. However, he died ofextrahepatic recurrence in
lymph nodes 16 months after the gastrectomy.
Case2
This 52-year-old woman had numerous scattered meta-
stases in both hepatic lobes. The primary gastric tumour
was in the cardia. She underwent total gastrectomy with
lymph node dissection including the left gastric, splenic,
celiac and common hepatic arterial regions. Microscopic
metastases were found in the regional and splenic nodes.
Implantation ofthe vascular occluder and the cannula was
also performed. The occlusion therapy for hour twice a
daywas started at 5POD and continued for year. MMC,
10mg and 5-FU, 250mgwere administered intra-arterially
at 11 POD and the infusion of5-FU in a dos of250mg/day
was repeated for 19 consecutive days. She repeatedly had
these cytotoxic drugs, total doses ofwhich were 46mg for
MMC and 19750 mg for 5-FU as an out-patient. Oral
administrationofHCFU 300mg/daywas also added from 3
months to 5 months after operation. Fivemonths after the
therapy started the multiple metastatic lesions in the entire
liver almost disappeared and all the residual lesions were
cystic (Fig. 2) The value ofCEA decreased from 75.4 ng/ml
to 4.6 ng/ml by the same time. She lived a normal life and
continued the occlusion therapy at home for a year. She
however died owing to intra-abdominal lymph node and
bone metastases though the hepatic tumours remained
well controlled.
Case3
This 72-year-oldman underwent partial gastrectomy with
R2 lymph node dissection. Lymph node metastases were
not found histologically. For a massive metastasis in the
right hepatic lobe, hepatic bisegmentectomy (segment VI
and VII) was performed. However, 6 months after ope-
ration, multiple recurrences were found in the remnant
liver. Implantation ofa vascular occluder and cannulation
were performed. The occlusion therapy was repeated
from 7 POD but it was ceased at 24 POD due to liver
dysfunction. The hyperbilirubinemia required plasmaphe-
resis at 41 POD and 63 POD. The occlusion therapy was
restarted at 51 POD with an expectation that regression of
tumours by the treatment would allow the liver function to
recover. However, the patient died of systemic bleeding
due to liver failure. Ironically, autopsy revealed total
necrosis of all the hepatic tumours.
This case urged us to reconsider the indication and
timing ofthe therapy.
Case 4
This 73-year-old patient underwent partial gastrectomy
with R2 lymph node dissection. Microscopic invasion of
the resected nodes was not seen. The liver was involved
with numerous massive tumours in the both lobes. After
hepatic dearterialization, the entire surface of liver was
covered with a polyethylene sheath to prevent collateral
development. The occlusion therapy was started from 8
POD in spite ofa high total bilirubin 132 gm/1. The patient
tolerated the procedure but CT scan revealed a left
subphrenic abscess after 3 weeks therapy, which was
drained the next day. However, he died due to liver failure
triggered by the abscess.
Case 5
This 66-year-oldman had undergone partial gastrectomy
with R3 lymph node dissection. Regional and hepato-
duodenal lymph node metastases were found histo-
logically. A massive tumour occupied the right hepatic
lobe and the numerous scattered metastases were seen in
both lobes. The occlusion therapy was started at 8 POD.
Intra-arterial infusions ofMMC in a dose of 2 mg/day
everyday and Epirubicin, 10 mg, twice a week were
repeated for a month. Additional administrations were
repeated thereafter. The ischemic therapy was also
repeated for 4 months but then ceased due to rupture of
the balloon occluder. Three months after the therapy, the
massive metastasis in the fight lobe changed into a calcified
lesion and other small tumours almost disappeared. The
CEA level also decreased from 302 ng/ml at 13POD to 10.7
ng/ml at 4 months. He is alive at 15 months after the
initiation of the current therapy although minute lung
metastases are present.
DISCUSSION
The concept oftransient hepatic dearterialization for liver
tumours was first proposed in 19765, after a number of
strategies such as hepatic artery ligation and hepatic
dearterialization, in combination with or without anti-
cancer drug infusion6-8. However, the result of conven-
tional hepatic dearterialization was not satisfactory except
for metastatic carcinoid disease in terms ofsurvival and
complication rates as compared with intra-arterial
infusion of 5-Fluorouracil alone 1. This new method of178 T. KIMOTO et al.
Figure 2 CT scans in case 2. A before operation. B 5 months after the occlusion therapy.
repeated short-term occlusion of the hepatic artery was
developed by Bengmark et al. 3 following studies
showing that it can prevent hepatic arterial collaterals4.
The possible implication of oxygen free radicals in this
therapy was suggested by the same group5. Only two out
of thirteen patients developed collaterals during the
repeated temporary dearterialization and that at least
six patients demonstrated the antitumour effect of this
therapy3.
We have also used this method for unresectable
primary and secondary liver since 1988 and now present
five cases ofmultiple liver metastases from gastric cancer.
In all the five cases, tumour regression was obtained,
amongwhich three demonstrated more than 70% tumour
reduction. TheCEA levels also became normal or almost
normal during the therapy in four patients. The remaining
patient had a lowCEA value at the start ofthe occlusion
therapy (Fig.3). The density oftumours became lower byLIVER METASTASESFROM GASTRICCANCER 179
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even in the presence of multiple liver metastases.
Although all three patients who survived for a long time
finally suffered from distant lymph node or lung
metastases, the liver tumours remained well controlled.
They had a good performance status with the repeated
hepatic dearterialization therapy at home. These results
seem to indicate that this therapy has some use in the
treatment of unresectable liver metastases from gastric
cancer.
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COMMENTRY
This is an interesting report on 5 patients with advanced
gastric cancer that has proved to be very resistant to
almost any kind of treatment. Most surgeons would
hesitate to perform such aggressive treatment because of
the very poor prognosis indeed. Although an occasional
patient may have a long survival even without treatment it
is hard to imagine that they would survive for such long
periods as was seen in three ofthe patients. I find it striking
that they all had a dramatic response, radiological as well
as biochemical. To my knowledge chemotherapy alone
has not been able to show the same response, the addition
ofrepeated dearterializations must have been responsible.
Previous attempts to use ischemic therapy have been
disappointing. Considerable palliation seems to have been
offered to these five patients with tolerable side effects;
three of them managed to perform the dearterializa-
tions at home.
One can argue that the report comprises only five
patients and, ofcourse, the chance can never be ruled out.
However, based on these favourable responses and
survival a randomised trial would seem appropriate.
Both hepatic artery ligation and the more extensive
permanent dearterilization fail to achieve a sustained
tumour growth delay because ofa speedy development of
collaterals. Intermittent but repeated dearterialization
seems to be able to offer a longer growth delay in part
owing to a prevention ofcollaterals. We have previously
used dearterialization for hour/day. However, based
on recent results (in a rat liver-tumourmodel) 2 hours/day
seems to be the optimal period in retarding liver tumour
growth and has led us to change our protocol.
1. Repeated dearterialization of an experimental liver
tumour: short-and long-term results.
Li Qing Wang, Bo G Persson and Stig Bengmark. J Surg Res; In
Press
BoG Persson
Lund, Sweden